Abstracts tagged "Damage Index"

Abstract Number: L13 • ACR Convergence 2024
Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Zahi Touma¹, Ian Bruce², Richard A. Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Kellyn Arnold⁸, Hopin Lee⁸, Eleanor Ralphs⁸, Danuta Kielar⁹, Aleksander Bedenkov⁹ and Miina Waratani⁹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Queen's University Belfast, Belfast, United Kingdom, ³Northwell Health, Manhasset, NY, ⁴Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶Astrazeneca, Mississauga, ON, Canada, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸IQVIA, London, United Kingdom, ⁹Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
Abstract Number: 2070 • ACR Convergence 2024
Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Margherita Giannini¹, Anne-Laure Charles², Julien Blaess³, Rose-Marie Javier⁴, Bernard Geny⁵ and Alain Meyer⁶, ¹UR3072, Physiology Department, University Hospital of Strasbourg, Strasbourg, France, ²UR3072, University of Strasbourg, Strasbourg, France, ³Physiology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁴Rheumatology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁵UR3072, Physiology Department, University Hospital of StrasbourgUniversity Hospital of Strasbourg, STRASBOURG, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In inflammatory myopathies (IM), although several treatments effectively control disease activity, a high proportion of patients display sustained disability (damage). Damage might be reversed…
Abstract Number: 2308 • ACR Convergence 2024
Characterization of Damage in a Primary Sjogren’s Syndrome Cohort
Ana Mafalda Abrantes¹, Pedro Gaspar² and David Isenberg³, ¹Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Lisbon, Portugal, ²Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ³University College London, London, United Kingdom
Background/Purpose: Damage is irreversible and represents a permanent loss in organ function. Outcome measures are critical for minimizing and prevent damage acquisition. There are two…
Abstract Number: 2309 • ACR Convergence 2024
Damage Accrual Predicts the Development of Lymphoma in Primary Sjogren’s Syndrome
Ana Mafalda Abrantes¹, Pedro Gaspar² and David Isenberg³, ¹Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Lisbon, Portugal, ²Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ³University College London, London, United Kingdom
Background/Purpose: Primary Sjogren Syndrome (pSS) is an autoimmune disease affecting primarily exocrine glands. Over a quarter of patients have systemic involvement, which includes the development…
Abstract Number: 2318 • ACR Convergence 2024
Does the Time Interval Between the Onset of Psoriasis and Psoriatic Arthritis Impact Disease Presentation and Outcomes?
Fadi Kharouf¹, Pankti Mehta², Shangyi Gao², Daniel Pereira³, Richard Cook⁴, Dafna Gladman⁵ and Vinod Chandran⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis typically precedes psoriatic arthritis (PsA), with a variable transition period. In this study, we aimed to explore whether the time interval between the…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
Abstract Number: 2374 • ACR Convergence 2024
Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Omer Uludag¹, Sarvan Aghamuradov¹, Cansu Erel Gezegen², Marjan Jabbarli², Ismat Habibov², Ahmet Oguz Celik², Yasemin Yalcinkaya¹, Ahmet Gul¹, Murat Inanc¹ and Bahar Artim Esen¹, ¹Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey
Background/Purpose: Thrombocytopenia has been reported at frequencies ranging from 10 to 40 % in different cohorts. Treatment can be challenging and due to its considerable…
Abstract Number: 0118 • ACR Convergence 2024
Performance of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort
Erik Cimé-Aké¹, Gabriela Hernández-Molina², Amaya Llorente-Chávez³ and Eduardo Martin Nares², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Hematology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: The 2023 ACR/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) were recently published. The new criteria require an entry criterion and employe a…
Abstract Number: 2375 • ACR Convergence 2024
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Burak Kundakci¹, Megan Barber², Ann E. Clarke², Sindhu Johnson³, Ian Bruce¹ and On behalf of the revised SLE organ damage index (SDI) collaborators⁴, ¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to…
Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Evelyn Aranda Cano¹, Jessica Roldan Ortega², Yaneli Juárez-Vicuña³, Fausto Sánchez Muñoz⁴, Itzel Palafox Sosa⁵, Luz Angelica Viruel-Mejia⁶, David Vera Bustamante⁷, Luis H. Silveira Torre⁸, Angélica Vargas Guerrero⁹, Mayra Nadia Quintanar-Cuevas¹⁰, Erick Giovanny Bautista Jímenez¹¹ and Laura Aline Martinez-Martinez¹², ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, ⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁷Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁸Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁹Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ¹⁰Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ¹¹Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, ¹²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
Abstract Number: 2403 • ACR Convergence 2024
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Fernando A Oliveira¹, Fabiana Moura², Ana Flávia Dias³, Claudia Santoro³, Fernando Pereira², Rosa Telles² and Cristina Lanna², ¹Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ²Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
Abstract Number: 0123 • ACR Convergence 2024
The Impact of Sedentary Behavior and Physical Activity Level on Clinical Parameters and Quality of Life in Patients with Primary Antiphospholipid Syndrome (PAPS)
Carla Silva¹ and Danieli Andrade², ¹University of Sao Paulo, Salvador, Bahia, Brazil, ²University of São Paulo, São Paulo, SP, Brazil
Background/Purpose: PAPS is an autoimmune disease marked by thrombosis, obstetric poor outcomes and antiphospholipid antibodies. Despite treatment, APS is associated with high morbidity and mortality,…
Abstract Number: 2443 • ACR Convergence 2024
The Clinical Phenotype of Anti-Th/To+ Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort
Liala Moschetti¹, Eleonora Pedretti², Francesco Bonomi³, María Martín López⁴, Fabio Cacciapaglia⁵, cristiana sieiro santos⁶, Gianluca Moroncini⁷, Yannick Allanore⁸, Joana Caetano⁹, Brigitte Granel¹⁰, Laura Groseanu¹¹, Maria De Santis¹², Masataka Kuwana¹³, Veronica Codullo¹⁴, Mariana Pereira Silva¹⁵, Pietro Bearzi¹⁶, Laura Belloli¹⁷, Alida Taberner-Cortés¹⁸, Cristina Maglio¹⁹, Francesco Del Galdo²⁰, Corrado Campochiaro²¹, Marie-Elise Truchetet²², Giovanna Cuomo²³, Magda Parvu²⁴, Florenzo Iannone²⁵, Patricia Carreira²⁶, Serena Guiducci²⁷, Franco Franceschini¹, Paolo Airò¹ and Maria-Grazia Lazzaroni¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ³Division of Rheumatology, Scleroderma Unit, University of Florence, AOU Careggi Firenze; Italy, Firenze, Italy, ⁴General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁶Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁷Marche Polytechnic University, Ancona, Italy, ⁸Rheumatology department, Université Paris Cité, Cochin Hospital of Paris; France, Paris, France, ⁹Systemic Autoimmune Diseases Unit, Fernando Fonseca Hospital, Amadora; Portugal, Amadora, Portugal, ¹⁰Service de Médecine Interne Hôpital Nord de Marseille; France, Marseille, France, ¹¹Spitalul Sfanta Maria, Bucharest, Romania, ¹²Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital and Biomedical Sciences, Hu-manitas University, Milan; Italy, Milan, Italy, ¹³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁴Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁵Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa; Portugal, Lisboa, Portugal, ¹⁶Immunorheumatology Unit, Università Campus Bio-Medico University of Roma; Italy, Roma, Italy, ¹⁷Niguarda Hospital, Milan, Milan, Italy, ¹⁸Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹University of Gothenburg, Gothenburg, Sweden, ²⁰University of Leeds, Leeds, United Kingdom, ²¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²²Bordeaux University Hospital, Bordeaux, France, ²³Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²⁴Colentina Clinical Hospital, Rheumatology Department, Bucharest; Romania, Bucharest, Romania, ²⁵Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²⁶Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ²⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: To evaluate clinical associations of anti-Th/To antibodies in SSc patients in a multicentre international cohort, focusing on interstitial lung disease (ILD), pulmonary arterial hypertension…
Abstract Number: 0128 • ACR Convergence 2024
Damage Index in Patients with Thrombotic Antiphospholipid Syndrome (DIAPS) Version 2.0: One Single Center Pilot Study
Laura Aline Martinez-Martinez¹, Mary-Carmen Amigo² and María Victoria Goycochea Robles³, ¹Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, ²ABC Medical Center, Mexico City, Estado de México, Mexico, ³Universidad Nacional Autonoma de Mexico, Mexico city, Distrito Federal, Mexico
Background/Purpose: Antiphospholipid antibody syndrome is the main acquired thrombophilia in the rheumatological area. It is characterized by thrombotic events and obstetric morbidity associated with the…
Abstract Number: 0185 • ACR Convergence 2024
New and Severe Damage in a Prevalent Lupus Cohort Through the Lens of Demographic and Neighborhood Disparities
Jonathan Katz¹, Ang Yu², Felix Elwert², Robert Greenlee³, David Gazeley⁴, Ann Rosenthal⁵, Jenna Cormier⁵, Bryn Sutherland⁵, Shalvi Parikh⁶, Yiran Jiang⁷ and Christie Bartels⁸, ¹University of Wisconsin Hospitals and Clinics, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³Marshfield Clinical Research Institute, Marshfield, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mississippi Delta Family Medicine Residency, Greenville, MS, ⁷Annapolis Rheumatology, Washington, DC, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) disproportionally affects minoritized populations. SLE damage, assessed by SLICC/ACR Damage Index (SDI), is higher in Black than in White US…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].